

FORM PTO-1390
(REV 10-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

534037 TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
09/926,138INTERNATIONAL APPLICATION NO.
PCT/JP00/01494INTERNATIONAL FILING DATE
13 March 2000PRIORITY DATE CLAIMED
18 March 1999TITLE OF INVENTION
ENZYMATIC FLUOROMETRIC ASSAY OF cAMP AND ADENYLATE CYCLASE

APPLICANT(S) FOR DO/EO/US

Atsushi SUGIYAMA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A FIRST preliminary amendment.
- A SECOND or SUBSEQUENT preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:

English Translation of International
Preliminary Examination Report

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/926,138	INTERNATIONAL APPLICATION NO. PCT/JP00/01494	ATTORNEY'S DOCKET NUMBER 534037 mo																
		CALCULATIONS PTO USE ONLY																
<p>17. <input type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO: \$860.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p>																		
ENTER APPROPRIATE BASIC FEE AMOUNT = <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/>																		
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">CLAIMS</th> <th style="width: 30%;">NUMBER FILED</th> <th style="width: 30%;">NUMBER EXTRA</th> <th style="width: 25%;">RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>- 20 =</td> <td></td> <td>X \$18.00 \$</td> </tr> <tr> <td>Independent claims</td> <td>- 3 =</td> <td></td> <td>X \$80.00 \$</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td></td> <td>+ \$270.00 \$</td> </tr> </tbody> </table>			CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	- 20 =		X \$18.00 \$	Independent claims	- 3 =		X \$80.00 \$	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00 \$
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE															
Total claims	- 20 =		X \$18.00 \$															
Independent claims	- 3 =		X \$80.00 \$															
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00 \$															
TOTAL OF ABOVE CALCULATIONS = <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/>																		
<p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="width: 100%;">SUBTOTAL =</th> <th style="width: 100%; text-align: right;">\$</th> </tr> </thead> <tbody> <tr> <td colspan="2">Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td style="text-align: right;">+ \$</td> </tr> </tbody> </table>			SUBTOTAL =		\$	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$										
SUBTOTAL =		\$																
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$																
TOTAL NATIONAL FEE = <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/>																		
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="width: 100%;">TOTAL FEES ENCLOSED =</th> <th style="width: 100%; text-align: right;">\$</th> </tr> </thead> <tbody> <tr> <td colspan="2"></td> <td style="text-align: right;">Amount to be refunded: <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/></td> </tr> <tr> <td colspan="2"></td> <td style="text-align: right;">charged: <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/></td> </tr> </tbody> </table>			TOTAL FEES ENCLOSED =		\$			Amount to be refunded: <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/>			charged: <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/>							
TOTAL FEES ENCLOSED =		\$																
		Amount to be refunded: <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/>																
		charged: <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/> \$ <input style="width: 100px; border: 1px solid black; border-left: none; border-right: none;" type="text"/>																
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>10-1213</u>. A duplicate copy of this sheet is enclosed.</p>																		
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>																		
<p>SEND ALL CORRESPONDENCE TO:</p> <p>Eric S. Spector JONES, TULLAR & COOPER, P.C. P.O. Box 2266 Eads Station Arlington, Virginia 22202</p>																		
<p>SIGNATURE:  Eric S. Spector NAME 22495 REGISTRATION NUMBER</p>																		

PATENT COOPERATION TREATY

PCT
**NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

(PCT Rule 72.2)



From the INTERNATIONAL BUREAU

To:

AOYAMA, Tamotsu
Aoyama & Partners
IMP Building, 3-7, Shiromi 1-
chome, Chuo-ku
Osaka-shi, Osaka 540-0001
JAPON

Date of mailing (day/month/year)
30 August 2001 (30.08.01)

Applicant's or agent's file reference
661450

International application No.
PCT/JP00/01494

IMPORTANT NOTIFICATION

International filing date (day/month/year)
13 March 2000 (13.03.00)

Applicant
FUSO PHARMACEUTICAL INDUSTRIES, LTD. et al

1. Transmittal of the translation to the applicant.

The International Bureau transmits herewith a copy of the English translation made by the International Bureau of the international preliminary examination report established by the International Preliminary Examining Authority.

2. Transmittal of the copy of the translation to the elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following elected Offices requiring such translation:

EP, AT, AU, CA, CH, CN, CZ, FI, NO, NZ, PL, RO, RU, SK, US

The following elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AP, EA, AE, AL, AM, AZ, BA, BB, BG, BR, BY, CR, CU, DE, DK, DM, DZ, EE, ES, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, PT, SD, SE, SG, SI, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, OA

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report.

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO
34, ch. min des Cévennes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Authorized officer

Telephone No. (41-22) 338.83.38

Translation

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 661450	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/JP00/01494	International filing date (<i>day/month/year</i>) 13 March 2000 (13.03.00)	Priority date (<i>day/month/year</i>) 18 March 1999 (18.03.99)
International Patent Classification (IPC) or national classification and IPC C12Q 1/06, 1/34, 1/42, 1/48		
Applicant	FUSO PHARMACEUTICAL INDUSTRIES, LTD.	

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of <u>3</u> sheets, including this cover sheet.
<input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
These annexes consist of a total of _____ sheets.
3. This report contains indications relating to the following items:
I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 24 August 2000 (24.08.00)	Date of completion of this report 24 January 2001 (24.01.2001)
Name and mailing address of the IPEA/JP	Authorized officer
Facsimile No.	Telephone No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP00/01494

I. Basis of the report**1. With regard to the elements of the international application:*** the international application as originally filed the description:

pages _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

 the claims:

pages _____, as originally filed

pages _____, as amended (together with any statement under Article 19)

pages _____, filed with the demand

pages _____, filed with the letter of _____

 the drawings:

pages _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

 the sequence listing part of the description:

pages _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

 the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:** contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.**4. The amendments have resulted in the cancellation of:** the description, pages _____ the claims, Nos. _____ the drawings, sheets/fig. _____**5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).****

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP00/01494

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	1-22	YES
	Claims		NO
Inventive step (IS)	Claims	1-22	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-22	YES
	Claims		NO

2. Citations and explanations**Claims 1-22**

Documents 1 and 2 cited in the ISR [US, 5618665, A (Regents of the University of Minnesota), 31 May, 1994 (31.05.94) and EP, 781851, A1, (Kikkoman Corporation), 2 July, 1997 (02.07.97)] neither describe nor suggest the feature of the invention of claim 1, that is, using the three enzymes apyrase, alkaline phosphatase and adenosin deaminase in combination to remove non-cyclic adenine nucleotides and endogenous glycose-6-phosphate. On the other hand, in the invention of claim 1, combined use of the above three enzymes produces a remarkable effect that could not be expected from the above-mentioned documents 1 and 2 and so the invention appears to be novel and to involve an inventive step.

The subject matters of claims 2-20, which technically limit and embody the invention of claim 1, and the subject matters of claims 21 and 22 related to a kit for carrying out the invention of claim 1, also appear to be novel and to involve an inventive step.